OGN News and Press, Organon & Co. From 05/28/24

2024-05-28 10:30:08 ET Summary WisdomTree U.S. SmallCap Dividend Fund holds about 600 small and micro cap stocks weighted based on dividends. DES is heavy in financials, but well diversified across holdings. DES' valuation, quality and 12-month return are fine, but its histori...

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia ® and Xgeva ® (denosumab) biosimilar. Denosumab has been a...

2024-05-23 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-11 06:58:33 ET Summary Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff h...

2024-05-09 08:15:00 ET Summary Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics. Teva has a positive business outlook for 2024, w...

2024-05-08 09:10:25 ET Summary Organon released its Q1 2024 results on May 2, and the company's stock has nearly doubled since its low just five months ago. In this update, I take a look at the pharmaceutical and biosimilars company's Q1 earnings report and determine whether the m...

2024-05-08 04:06:42 ET More on Organon Four Reasons Why Organon Stock Is A Good Buy Organon & Co. (OGN) Q1 2024 Earnings Call Transcript Organon Stock Is Still Worth A Look Organon Non-GAAP EPS of $1.22 beats by $0.29, revenue of $1.62B beats by $60M ...

Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with...

2024-05-07 12:43:50 ET Summary OGN has underperformed its healthcare peers and the benchmark over the past year, but this could change going forward. The company's dominant women's health product- Nexplanon is looking at double-digit growth in sales this year, even as market loss ...

2024-05-07 08:21:25 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Read the full article on Seeking Alpha For further details see: Organon plans to offer $1B in senior notes